DK0986387T3 - Farnesyl transferase inhibitorer i kombination med HMG CoA reduktase inhibitorer til behandling af cancer - Google Patents

Farnesyl transferase inhibitorer i kombination med HMG CoA reduktase inhibitorer til behandling af cancer

Info

Publication number
DK0986387T3
DK0986387T3 DK98921688T DK98921688T DK0986387T3 DK 0986387 T3 DK0986387 T3 DK 0986387T3 DK 98921688 T DK98921688 T DK 98921688T DK 98921688 T DK98921688 T DK 98921688T DK 0986387 T3 DK0986387 T3 DK 0986387T3
Authority
DK
Denmark
Prior art keywords
inhibitors
cancer
treatment
combination
coa reductase
Prior art date
Application number
DK98921688T
Other languages
English (en)
Inventor
Shama Mohammed Kajiji
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DK0986387T3 publication Critical patent/DK0986387T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK98921688T 1997-06-16 1998-06-05 Farnesyl transferase inhibitorer i kombination med HMG CoA reduktase inhibitorer til behandling af cancer DK0986387T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4963897P 1997-06-16 1997-06-16
PCT/IB1998/000881 WO1998057633A1 (en) 1997-06-16 1998-06-05 FARNESYL TRANSFERASE INHIBITORS IN COMBINATION WITH HMG CoA REDUCTASE INHIBITORS FOR THE TREATMENT OF CANCER

Publications (1)

Publication Number Publication Date
DK0986387T3 true DK0986387T3 (da) 2003-07-14

Family

ID=21960890

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98921688T DK0986387T3 (da) 1997-06-16 1998-06-05 Farnesyl transferase inhibitorer i kombination med HMG CoA reduktase inhibitorer til behandling af cancer

Country Status (37)

Country Link
EP (1) EP0986387B1 (da)
JP (1) JP3713051B2 (da)
KR (1) KR100392573B1 (da)
CN (1) CN1259868A (da)
AP (1) AP9801261A0 (da)
AR (1) AR013090A1 (da)
AT (1) ATE235905T1 (da)
BG (1) BG103946A (da)
BR (1) BR9810616A (da)
CA (1) CA2294399C (da)
CO (1) CO4950607A1 (da)
DE (1) DE69812933T2 (da)
DK (1) DK0986387T3 (da)
DZ (1) DZ2518A1 (da)
EA (1) EA199901043A1 (da)
ES (1) ES2196559T3 (da)
GT (1) GT199800081A (da)
HN (1) HN1998000091A (da)
HR (1) HRP980328B1 (da)
HU (1) HUP0004624A3 (da)
ID (1) ID23014A (da)
IL (1) IL132765A0 (da)
IS (1) IS5259A (da)
MA (1) MA24569A1 (da)
NO (1) NO996206L (da)
NZ (1) NZ500662A (da)
OA (1) OA11231A (da)
PA (1) PA8453601A1 (da)
PE (1) PE82899A1 (da)
PL (1) PL337651A1 (da)
PT (1) PT986387E (da)
SK (1) SK169699A3 (da)
TN (1) TNSN98088A1 (da)
TR (1) TR199903074T2 (da)
UA (1) UA57081C2 (da)
WO (1) WO1998057633A1 (da)
ZA (1) ZA985182B (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID27933A (id) 1998-05-12 2001-05-03 Warner Lambert Co Gabungan protein farnesiltransferase dan inhibitor hmg-coa reduktase serta penggunaannya untuk mengobati kanker
WO2000016778A1 (en) * 1998-09-24 2000-03-30 Merck & Co., Inc. A method of treating cancer
EP1006113A1 (en) 1998-12-02 2000-06-07 Pfizer Products Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
WO2000067737A2 (en) * 1999-05-07 2000-11-16 The Brigham And Women's Hospital, Inc. USE OF HMGCoA REDUCTASE INHIBITORS IN THE PREVENTION OF DISEASES WHOSE PATHOGENESIS IS DEPENDENT ON NEOVASCULARIZATION
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
JP2004516287A (ja) 2000-12-19 2004-06-03 ファイザー・プロダクツ・インク 6−[(4−クロロ−フェニル)−ヒドロキシ−(3−メチル−3h−イミダゾール−4−イル)−メチル]−4−(3−エチニル−フェニル)−1−メチル−1h−キノリン−2−オン,2,3−ジヒドロキシブタン二酸塩の結晶形および製造方法
JP4092203B2 (ja) 2000-12-21 2008-05-28 ニトロメッド,インク. 新規のシクロオキシゲナーゼ2選択的阻害剤としての置換アリール化合物、組成物、および使用方法
US20020151563A1 (en) * 2001-03-29 2002-10-17 Pfizer Inc. Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
US6740757B2 (en) 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
TWI297606B (en) * 2004-01-16 2008-06-11 Nat Health Research Institutes Cancer therapy
US8168667B2 (en) 2006-05-31 2012-05-01 Galapagos Nv Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such
GB2463514C (en) 2008-09-11 2018-09-26 Galapagos Nv Imidazolidine compounds and uses therefor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997005902A1 (fr) * 1995-08-09 1997-02-20 Banyu Pharmaceutical Co., Ltd. Composition medicinale

Also Published As

Publication number Publication date
CO4950607A1 (es) 2000-09-01
ES2196559T3 (es) 2003-12-16
IL132765A0 (en) 2001-03-19
NZ500662A (en) 2001-10-26
PT986387E (pt) 2003-06-30
OA11231A (en) 2003-05-26
TNSN98088A1 (fr) 2005-03-15
GT199800081A (es) 1999-12-07
AU7445998A (en) 1999-01-04
HUP0004624A3 (en) 2002-11-28
ID23014A (id) 1999-12-30
PA8453601A1 (es) 2000-05-24
SK169699A3 (en) 2000-06-12
CA2294399C (en) 2004-03-16
ATE235905T1 (de) 2003-04-15
MA24569A1 (fr) 1998-12-31
UA57081C2 (uk) 2003-06-16
HRP980328A2 (en) 1999-04-30
IS5259A (is) 1999-11-19
EP0986387B1 (en) 2003-04-02
DZ2518A1 (fr) 2003-02-01
NO996206L (no) 2000-02-15
CN1259868A (zh) 2000-07-12
NO996206D0 (no) 1999-12-15
JP2000513031A (ja) 2000-10-03
HN1998000091A (es) 1999-09-29
DE69812933T2 (de) 2003-11-06
JP3713051B2 (ja) 2005-11-02
BR9810616A (pt) 2000-09-12
BG103946A (bg) 2000-07-31
KR20010013839A (ko) 2001-02-26
AP9801261A0 (en) 1999-12-11
DE69812933D1 (de) 2003-05-08
EP0986387A1 (en) 2000-03-22
PL337651A1 (en) 2000-08-28
WO1998057633A1 (en) 1998-12-23
EA199901043A1 (ru) 2000-06-26
HRP980328B1 (en) 2002-06-30
CA2294399A1 (en) 1998-12-23
HUP0004624A2 (hu) 2001-10-28
AR013090A1 (es) 2000-12-13
TR199903074T2 (xx) 2000-05-22
KR100392573B1 (ko) 2003-07-23
PE82899A1 (es) 1999-08-26
ZA985182B (en) 1999-12-17
AU724676B2 (en) 2000-09-28

Similar Documents

Publication Publication Date Title
DK2028186T3 (da) Hepatitis C inhibitor tri-peptider
DK1147083T3 (da) Arylpiperazinyl-cyclohexylindolderivater til behandling af depression
DK1183033T3 (da) Pyrrolotriazininhibitorer af kinaser
EE200100659A (et) Diaminotiasoolid ja nende kasutamine proteiinikinaaside pärssimiseks
DK1073658T3 (da) Pyrazolopyrimidinon-cGMP PDE5-inhibitorer til behandling af sexualforstyrrelse
DK2412368T3 (da) Sammensætning til behandling af ar
NO20002121D0 (no) Benzotiazol-protein-tyrosin-kinaseinhibitorer
DK1292594T3 (da) Quinazolinderivater til behandling af tumorer
DK0942754T3 (da) Konjugater anvendelige til behandlingen af prostatacancer
DE69711020D1 (de) Thiazole derivate als protein kinase c inhibitoren
DK1032408T3 (da) Galenisk præparat til forebyggelse og behandling af leverkarcinom
DK0986387T3 (da) Farnesyl transferase inhibitorer i kombination med HMG CoA reduktase inhibitorer til behandling af cancer
DK1176964T3 (da) Brug af ET743 til behandling af cancer
DK1250152T3 (da) Synergistisk sammensætning indeholdende hyaluronsyre til behandling af cancer
ITMI981670A0 (it) Derivati ftalazinici inibitori della fosfodiesterasi 4
DK0917464T3 (da) Anvendelse af aminer til fremstilling af lægemidler til forebyggelse af tumorcelleproliferation
FI980860A0 (fi) Laserarrangemang med reglerbar vaoglaengd
NO20005680L (no) Kombinasjoner av protein-farnesyltransferase og HMG CoA reduktase inhibitorer og anvendelse derav for behandling av cancer
DK1100499T3 (da) Anvendelse af eletriptan til forebyggelse af migrænetilbagevendelse
MA24877A1 (fr) INHIBITEURS DE PROTéASES
SI0986387T1 (en) FARNESYL TRANSFERASE INHIBITORS IN COMBINATION WITH HMG CoA REDUCTASE INHIBITORS FOR THE TREATMENT OF CANCER
DE69720957T2 (de) Ace-hemmer
NO20006314D0 (no) Prenyltransferase-inhibitorer
AU2002303182A1 (en) Farnesyl transferase inhibitors in combination with hmg coa reductase inhibitors for the inhibition for the treatment of cancer
DK1133290T3 (da) Anvendelse af acetylcholinesterase-inhibitorer til behandling af delirier